MAPS has received regulatory approval to conduct a study of smoked cannabis for symptoms of PTSD in veterans of war. The study evaluated safety and efficacy of four different potencies of cannabis.
The WeCan Study is an effort of MAPS to collect information about the efficacy of cannabis-based treatments for PTSD.
The WeCan Study is a Phase 2 clinical trial to test safety and efficacy of four different concentrations of cannabis in people with PTSD. This study explores whether smoked cannabis can help reduce PTSD symptoms in U.S. veterans with chronic, treatment-resistant PTSD.
Phase 2 Clinical Trial
Placebo-controlled, triple-blind, randomized crossover pilot study of the safety and efficacy of four different potencies of smoked cannabis in 76 Veterans with chronic, treatment-resistant PTSD. Participants were U.S. veterans, men or women, aged 18 or older with a diagnosis of PTSD that has not improved after trying either medication or psychotherapy. Enrollment for this study is complete.
Primary endpoint – Change in CAPS-5 Total Severity Score from baseline [Time Frame: Baseline, 3 weeks after randomization].